FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4244128297> ?p ?o ?g. }

• W4244128297 abstract "Background Thalassaemia major is a genetic disease characterised by a reduced ability to produce haemoglobin. Management of the resulting anaemia is through transfusions of red blood cells. Repeated transfusions result in excessive accumulation of iron in the body (iron overload), removal of which is achieved through iron chelation therapy. A commonly used iron chelator, deferiprone, has been found to be pharmacologically efficacious. However, important questions exist about the efficacy and safety of deferiprone compared to another iron chelator, desferrioxamine. Objectives To summarise data from trials on the clinical efficacy and safety of deferiprone and to compare the clinical efficacy and safety of deferiprone for thalassaemia with desferrioxamine. Search methods We searched the Group's Haemoglobinopathies Trials Register, MEDLINE, EMBASE, Biological Abstracts, ZETOC, Current Controlled Trials and bibliographies of relevant publications. We contacted the manufacturers of deferiprone and desferrioxamine. Most recent searches: June 2006. Selection criteria Randomised controlled trials comparing deferiprone with another iron chelator; or comparing two schedules of deferiprone, in people with transfusion‐dependent thalassaemia. Data collection and analysis Two authors independently assessed trial quality and extracted data. Missing data were requested from the original investigators. Main results Ten trials involving 398 people (range 10 to 144 people) were included. Nine trials compared deferiprone with desferrioxamine or a combination of deferiprone and desferrioxamine and one compared different schedules of deferiprone. There was little consistency between outcomes and little information to fully assess the methodological quality of most of the included trials. No trial reported long‐term outcomes (mortality and end organ damage). There was no consistent effect on reduction of iron overload between all treatment comparisons, with the exception of urinary iron excretion in comparisons of deferiprone with desferrioxamine. An increase in iron excretion levels favoured deferiprone in one trial and desferrioxamine in three trials, even though measurement of urinary iron excretion underestimates total iron excretion by desferrioxamine. Adverse events were recorded in trials comparing deferiprone with desferrioxamine. There was evidence of adverse events in all treatment groups. Adverse events in one trial were significantly more likely with deferiprone than desferrioxamine, risk ratio 2.24 (95% confidence interval 1.19 to 4.23). Authors' conclusions We found no reason to change current treatment recommendations, namely deferiprone is indicated for treating iron overload in people with thalassaemia major when desferrioxamine is contraindicated or inadequate. However, there is an urgent need for adequately‐powered, high quality trials comparing the overall clinical efficacy and long‐term outcome of deferiprone with desferrioxamine." @default.
• W4244128297 created "2022-05-12" @default.
• W4244128297 creator A5002450989 @default.
• W4244128297 creator A5009756710 @default.
• W4244128297 creator A5015207269 @default.
• W4244128297 creator A5062523448 @default.
• W4244128297 creator A5067817683 @default.
• W4244128297 creator A5083450977 @default.
• W4244128297 date "2007-07-18" @default.
• W4244128297 modified "2023-10-02" @default.
• W4244128297 title "Oral deferiprone for iron chelation in people with thalassaemia" @default.
• W4244128297 cites W1514932744 @default.
• W4244128297 cites W1965206528 @default.
• W4244128297 cites W1970516505 @default.
• W4244128297 cites W1979220493 @default.
• W4244128297 cites W1981998167 @default.
• W4244128297 cites W1993488925 @default.
• W4244128297 cites W1995491305 @default.
• W4244128297 cites W2001188398 @default.
• W4244128297 cites W2001204305 @default.
• W4244128297 cites W2004227612 @default.
• W4244128297 cites W2004392804 @default.
• W4244128297 cites W2010681387 @default.
• W4244128297 cites W2015979100 @default.
• W4244128297 cites W2016282041 @default.
• W4244128297 cites W2019985918 @default.
• W4244128297 cites W2021238211 @default.
• W4244128297 cites W2027084618 @default.
• W4244128297 cites W2031683173 @default.
• W4244128297 cites W2033288658 @default.
• W4244128297 cites W2033890227 @default.
• W4244128297 cites W2037107259 @default.
• W4244128297 cites W2038617022 @default.
• W4244128297 cites W2039715247 @default.
• W4244128297 cites W2040221822 @default.
• W4244128297 cites W2049030903 @default.
• W4244128297 cites W2051260674 @default.
• W4244128297 cites W2051651061 @default.
• W4244128297 cites W2055225978 @default.
• W4244128297 cites W2061809972 @default.
• W4244128297 cites W2063102842 @default.
• W4244128297 cites W2064765721 @default.
• W4244128297 cites W2067790584 @default.
• W4244128297 cites W2074897240 @default.
• W4244128297 cites W2077429231 @default.
• W4244128297 cites W2081568231 @default.
• W4244128297 cites W2088953057 @default.
• W4244128297 cites W2094357790 @default.
• W4244128297 cites W2106579993 @default.
• W4244128297 cites W2114845834 @default.
• W4244128297 cites W2115934082 @default.
• W4244128297 cites W2119692077 @default.
• W4244128297 cites W2120041716 @default.
• W4244128297 cites W2121974193 @default.
• W4244128297 cites W2126455979 @default.
• W4244128297 cites W2126619508 @default.
• W4244128297 cites W2128335522 @default.
• W4244128297 cites W2130235475 @default.
• W4244128297 cites W2134244300 @default.
• W4244128297 cites W2134704378 @default.
• W4244128297 cites W2137723066 @default.
• W4244128297 cites W2146921545 @default.
• W4244128297 cites W2148201779 @default.
• W4244128297 cites W2156237444 @default.
• W4244128297 cites W2165497130 @default.
• W4244128297 cites W2165890945 @default.
• W4244128297 cites W2166874051 @default.
• W4244128297 cites W2167251165 @default.
• W4244128297 cites W2172182806 @default.
• W4244128297 cites W2245642211 @default.
• W4244128297 cites W2284472461 @default.
• W4244128297 cites W2312723416 @default.
• W4244128297 cites W2317072972 @default.
• W4244128297 cites W2328653859 @default.
• W4244128297 cites W2330845108 @default.
• W4244128297 cites W2331162460 @default.
• W4244128297 cites W2334308892 @default.
• W4244128297 cites W2337170605 @default.
• W4244128297 cites W2340473515 @default.
• W4244128297 cites W2400148783 @default.
• W4244128297 cites W2409630370 @default.
• W4244128297 cites W2521084408 @default.
• W4244128297 cites W2980142174 @default.
• W4244128297 cites W4234077187 @default.
• W4244128297 cites W4253645796 @default.
• W4244128297 cites W4255852184 @default.
• W4244128297 doi "https://doi.org/10.1002/14651858.cd004839.pub2" @default.
• W4244128297 hasPublicationYear "2007" @default.
• W4244128297 type Work @default.
• W4244128297 citedByCount "23" @default.
• W4244128297 countsByYear W42441282972012 @default.
• W4244128297 countsByYear W42441282972013 @default.
• W4244128297 countsByYear W42441282972014 @default.
• W4244128297 countsByYear W42441282972015 @default.
• W4244128297 countsByYear W42441282972017 @default.
• W4244128297 countsByYear W42441282972020 @default.
• W4244128297 countsByYear W42441282972023 @default.
• W4244128297 crossrefType "reference-entry" @default.
• W4244128297 hasAuthorship W4244128297A5002450989 @default.
• W4244128297 hasAuthorship W4244128297A5009756710 @default.

• next